During South Korean President Yoon Suk Yeol’s state visit to the UK, several MoUs were signed between major universities as well as research institutes from South Korea and the UK. These MoUs emphasized fostering advanced biotechnology partnerships in areas ranging from synthetic biology and the development of AI-based drugs to brain research.
It is well to be noted that the Korea Research Institute of Bioscience and Biotechnology- KRIBB and the Korea Advanced Institute of Science & Technology- KAIST have gone on to enter into a MoU with Imperial College as well as the Innovation and Knowledge Center for Synthetic Biology SynbiCITE in the UK. This MoU means a collaborative effort between these institutions so as to engage in research cooperation, especially one that’s focused on synthetic biology.
The parties involved have come to an agreement to come up with a joint research center and move forward with strategic joint research and also the exchange of human resources. The most imperative and important aim of this deal happens to be to speed up as well as bring to light the development of core technologies when it comes to synthetic biology and biofoundry, as well as to aid the growth of the advanced biotechnology landscape which is based upon synthetic biology.
The Korea Brain Research Institute- KBRI and the Dementias Platform UK- DPUK have also announced their plans to elevate and upgrade their collaborative research efforts. The primary aim of this partnership is to come up with tailor-made treatment strategies for brain diseases and also create globally marketable diagnostics as well as treatments that can be readily applied across practical settings.
Apart from this, KRIBB and the University of Cambridge Milner Therapeutics Institute have also recently entered into an MoU so as to collaborate on research in the AI-driven drug development landscape.
